Qube Research & Technologies (QRT)
TARS icon

Qube Research & Technologies (QRT)’s Tarsus Pharmaceuticals TARS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.32M Sell
116,363
-207,651
-64% -$13.3M 0.01% 1444
2026
Q1 		$22.7M Sell
324,014
-77,227
-19% -$5.4M 0.03% 817
2025
Q4 		$32.9M Sell
401,241
-121,035
-23% -$9.04M 0.03% 676
2025
Q3 		$31M Buy
522,276
+62,840
+14% +$3.09M 0.03% 672
2025
Q2 		$18.6M Buy
459,436
+212,592
+86% +$9.57M 0.02% 929
2025
Q1 		$12.7M Buy
246,844
+148,848
+152% +$7.36M 0.01% 983
2024
Q4 		$5.43M Buy
97,996
+33,313
+52% +$1.51M 0.01% 1446
2024
Q3 		$2.13M Sell
64,683
-162,196
-71% -$4.56M ﹤0.01% 1738
2024
Q2 		$6.17M Buy
226,879
+193,516
+580% +$6.51M 0.01% 1165
2024
Q1 		$1.21M Buy
33,363
+27,535
+472% +$810K ﹤0.01% 2032
2023
Q4 		$118K Buy
+5,828
New +$97.3K ﹤0.01% 3044
2023
Q2 		– Sell
-10,352
Closed -$130K – 2998
2023
Q1 		$130K Buy
+10,352
New +$151K ﹤0.01% 2064

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TARS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Tarsus Pharmaceuticals (TARS) stake by 64% in Q2 2026, selling an estimated $13.3M and leaving 116,363 shares worth $7.32M. The position accounts for 0.01% of the portfolio, ranked #1444.

Qube Research & Technologies (QRT) first reported a position in TARS in Q1 2023 and has held it in 12 quarters since. The position peaked at $32.9M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Qube Research & Technologies (QRT) held 116,363 shares of Tarsus Pharmaceuticals worth $7.32M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 207,651 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $13.3M.
  • Tarsus Pharmaceuticals made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1444 holding.
  • Qube Research & Technologies (QRT) first reported a position in Tarsus Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • Qube Research & Technologies (QRT)'s Tarsus Pharmaceuticals position peaked at $32.9M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.